VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection

We studied the efficacy of the investigational drug VT-1161 against mucormycosis. VT-1161 had more potent in vitro activity against Rhizopus arrhizus var. arrhizus than against R. arrhizus var. delemar. VT-1161 treatment demonstrated dose-dependent plasma drug levels with prolonged survival time and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antimicrobial agents and chemotherapy 2015-12, Vol.59 (12), p.7815-7817
Hauptverfasser:	Gebremariam, Teclegiorgis, Wiederhold, Nathan P, Fothergill, Annette W, Garvey, Edward P, Hoekstra, William J, Schotzinger, Robert J, Patterson, Thomas F, Filler, Scott G, Ibrahim, Ashraf S
Format:	Artikel
Sprache:	eng
Schlagworte:	Amphotericin B - pharmacology Animals Antifungal Agents Antifungal Agents - blood Antifungal Agents - pharmacokinetics Antifungal Agents - pharmacology Experimental Therapeutics Immunocompromised Host Male Mice Mice, Inbred ICR Microbial Sensitivity Tests Mucormycosis Mucormycosis - drug therapy Mucormycosis - immunology Mucormycosis - microbiology Mucormycosis - mortality Pyridines Pyridines - blood Pyridines - pharmacokinetics Pyridines - pharmacology Rhizopus Rhizopus - drug effects Rhizopus - growth & development Rhizopus arrhizus Species Specificity Survival Analysis Tetrazoles Tetrazoles - blood Tetrazoles - pharmacokinetics Tetrazoles - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We studied the efficacy of the investigational drug VT-1161 against mucormycosis. VT-1161 had more potent in vitro activity against Rhizopus arrhizus var. arrhizus than against R. arrhizus var. delemar. VT-1161 treatment demonstrated dose-dependent plasma drug levels with prolonged survival time and lowered tissue fungal burden in immunosuppressed mice infected with R. arrhizus var. arrhizus and was as effective as high-dose liposomal amphotericin B treatment. These results support further development of VT-1161 against mucormycosis.
ISSN:	0066-4804 1098-6596
DOI:	10.1128/AAC.01437-15